An ascending multiple dose study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SAM-531 administered orally to healthy Japanese young male and elderly subjects
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2010
At a glance
- Drugs Cerlapirdine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Wyeth
- 05 Feb 2008 Status changed from recruiting to completed. Updated from ClinicalTrials.gov.
- 24 Jul 2007 New trial record.